SEARCH

SEARCH BY CITATION

References

  • 1
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90991.
  • 2
    Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 616976.
  • 3
    Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 2003; 171: 48937.
  • 4
    Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596604.
  • 5
    Marincola FM, Jafee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from. T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181273.
  • 6
    Zou W. Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 26374.
  • 7
    Drake CG, Jaffee E, Pardoll DM. Mechanism of immune evasion by tumors. Adv Immunol 2006; 90: 5181.
  • 8
    Kumartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55: 23745.
  • 9
    Chaput N, Confori R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27: 592031.
  • 10
    Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of. HLA expression during tumour development. Immunol Today 1993; 14: 4919.
  • 11
    Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered. HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 8995.
  • 12
    Garrido F, Festenstein H, Schirrmacher V. Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 1976; 261: 7057.
  • 13
    Ljunggren HG, Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 1990; 11: 23744.
  • 14
    Watson NF, Madjd Z, Splendlove I, Ellis IO, Scholefield JH, Durant LG. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118: 610.
  • 15
    Sáenz-López P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cózar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, Cabrera T. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 2010; 75: 1108.
  • 16
    Pellegrino MA, Ferrone S, Reisfeld RA, Irie RF, Golub SH. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer 1977; 40: 3641.
  • 17
    Robinson PJ, Sege K, Altevogt P, Peterson PA, Lundin L, Garrido F, Schirrmacher V. Unexpected H-2 antigen expression by mouse tumor cells, a cautionary note. Immunogenetics 1981; 13: 2615.
  • 18
    Stauss H, Linsk R, Fischer A, Watts S, Banasiak D, Haberman A, Clark I, Forman J, McMillan M, Schreiber H, Goodenow. Isolation of the MHC genes encoding the tumor specific class I antigens expressed on a murine fibrosarcoma J Immunogenet 1986; 13: 10111.
  • 19
    Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986; 322: 5023.
  • 20
    Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52: 19.
  • 21
    Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F. Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 2007; 69( 14th IHW Suppl 1): 2648.
  • 22
    Garrido F, Cabrera T, Accola RS, Bensa JC, Wodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, et al. HLA and cancer: 12th International Histocompatibility Workshop Study. In: CharronD, ed. HLA, genetic diversity of HLA. Functional and medical implications, vol. 1: EDK, Paris, France, 1997, 44552.
  • 23
    Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002; 51: 38996.
  • 24
    Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, Garcia A, Ruiz-Cabello F, Garrido F. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999; 83: 917.
  • 25
    Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000; 55: 4438.
  • 26
    Feenstra M, Vetkamp M, van Kuik J, Wiertsema S, Slootweg P, van dar Tweel J, de Weger R, Tilanus M. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999; 54: 23545.
  • 27
    Serrano A, Brady CS, Jimenez P, Duggan-Keen MF, Mendez R, Stern P, Garrido F, Ruiz-Cabello F. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics 2000; 51: 104752.
  • 28
    Jimenez P, Cabrera T, Mendez R, Esparza C, Cozar JM, Tallada M, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. A nucleotide insertion in exon 4 is responsible for the absence of expression of an. HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 2001; 53: 60610.
  • 29
    Wang Z, Marincola F, Rivoltini L, Parmiani G, Ferrone S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 1999; 190: 20515.
  • 30
    Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998; 52: 5209.
  • 31
    Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103: 75967.
  • 32
    Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible. HLA class I antigen alterations. Cancer Immunol Immunother 2008; 57: 172733.
  • 33
    Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, et al. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 2006; 12: 3297305.
  • 34
    Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta2 microglobuline in metastatic melanomas from five patients receiving immunotherapy. J Nat Cancer Inst 1996; 88: 1008.
  • 35
    Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta2-microglobulin messenger RNA. J Clin Invest 1993; 91: 68492.
  • 36
    Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta 2-microglobulin gene mutations. HLA-A2 allospecificity loss, and antigen-presenting machinery component downregulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005; 174: 146271.
  • 37
    Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 2007; 23: 34(1–11).
  • 38
    Abril E, Mendez RE, Garcia A, Serrano A, Cabrera T, Garrido F, Ruiz-Cabello F. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens 1996; 47: 3918.
  • 39
    Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 2008; 101: 24976.
  • 40
    Lopez-Nevot MA, Esteban F, Ferron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F, Garrido F. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59: 2216.
  • 41
    Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jiménez P, Pedrinaci S, Pawelec G, Ruiz-Cabello F, Garrido F. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 2008; 57: 71929.
  • 42
    Mendez R, Aptsiauri N, del Campo A, Rodríguez T, Garrido F, Garcia-Lora A. HLA and Melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 2009; 58: 150716.
  • 43
    Schrier PI, Versteeg R, Peltenburg LTC, Plomp AC, van't Veer LJ, Kruse-Wolters KM. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogenes-modulated HLA class I expression? Semin Cancer Biol 1991; 2: 7383.
  • 44
    Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for. HLA–ABC loss in bladder cancer. Int J Cancer 2005; 113: 60510.
  • 45
    Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 2003; 106: 5217.
  • 46
    Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11: 255260.
  • 47
    Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) downregulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 73742.
  • 48
    Ritz U, Momburg F, Pilch H, Huber C, Maurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19: 121120.
  • 49
    Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S. Characterization of human lymphocyte antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing downregulation. Clin Cancer Res 2003; 9: 17217.
  • 50
    Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001; 94: 24351.
  • 51
    Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD, Yang CS. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001; 22: 161523.
  • 52
    Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009; 58: 65364.
  • 53
    Vaessen RT, Houweling A, van der Eb AJ. Post-transcriptional control of class I MHC mRNA expression in adenovirus 12-transformed cells. Science 1987; 235: 14868.
  • 54
    Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007; 56: 70917.
  • 55
    Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008; 60: 43947.
  • 56
    Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 11758.
  • 57
    Koopman LA, Corver WE, Van Der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations at chromosome 6p cause frequent and heterogeneous HLA class I antigen loss in cervical cancer. J Exp Med 2000; 191: 96176.
  • 58
    Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, Ferron A, Garrido F. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004; 56: 24453.
  • 59
    Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, Lopez-Nevot MA, Garrido F. LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas. Immunogenetics 2006; 58: 50310.
  • 60
    Perez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, Lopez Nevot MA, Garrido F. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999; 53: 56972.
  • 61
    Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M. The β2 microglobuline mRNA in human DAUDI cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983; 2: 23943.
  • 62
    D'Urso CM, Wang Z, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2m gene expression. J Clin Invest 1991; 87: 28492.
  • 63
    Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W. Mechanisms of loss HLA class I expression on colorectal tumor cell. Tissue Antigens 1996; 47: 36471.
  • 64
    Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003; 61: 2119.
  • 65
    Kloor M, Becker C, Benner A, Woerner S, Gebert J, Ferrone S, Doeberitz MK. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005; 65: 641824.
  • 66
    Hsieh Ch, Hsu Y, Chang C, Liu H, Chuang K, Chuang C, Pang S, Hasumi K, Ferrone S, Liao S. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother 2009; 58: 395408.
  • 67
    Chen H, Gabriliovich D, Tampé R, Girgis K, Nadaf S, Carbone DP. A functionally defective allele of TAP1 result in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13: 13940.
  • 68
    Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61: 864750.
  • 69
    Del Campo A, Aptsiauri N, Mendez R, Zinchenko S, Vales A, Parchen A, Ward S, Ruiz-Cabello F, González-Aseguinolaza G, Garrido F. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol 2009; 70: 12535.
  • 70
    Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001; 91: 10919.
  • 71
    Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance, immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 71527.
  • 72
    Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995; 67: 15595.